Developer docs
API playgroundTry for free, no card

Search company profiles

Cellcolabs

Full company profile

uuid00025x1

Namestring
Cellcolabs
Legal namestring
Cellcolabs AB
Websiteurl
cellcolabs.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Cellcolabs is a Swedish biotech founded in 2021 that produces GMP-certified mesenchymal stem cells (MSCs) at industrial scale for both research supply and clinical therapeutic use. Manufacturing is conducted at a GMP-certified facility in Stockholm under oversight of the Swedish Medical Products Agency (Läkemedelsverket), with the underlying production protocol developed over 25+ years at Karolinska Institutet by Professor Katarina Le Blanc. A single bone marrow donation is reported to yield up to 200 therapeutic doses, and the company has publicly targeted a 90% reduction in MSC production cost by 2035 through scaled manufacturing.

The company serves four primary customer segments: university hospitals, academic and translational research institutions, biotech and pharmaceutical companies, and clinics offering MSC-based treatments. It operates dedicated regional vehicles — Cellcolabs Asia (Bangkok) for Southeast Asia commercialization and Cellcolabs Clinical (Bahamas/UAE) — which provide direct-to-clinic and DTC channels in jurisdictions where cell-therapy patient flows are accessible. The revenue model combines product sales of MSC batches to research customers, sponsorship of clinical trials at named academic medical centers (e.g., Rigshospitalet, InnoHK CNRM, Burjeel Medical City), and clinical treatments delivered through partner clinics.

Strategic positioning has shifted materially in 2025–2026: a $12M funding round closed in October 2025 to support international expansion, a new CEO with senior biotech/big-pharma pedigree (Vincent Metzler) was appointed in June 2026, and the company underwent a restructuring to prioritize B2B commercialization and orthopedic indications — notably knee osteoarthritis — alongside ongoing work in Sjögren's Syndrome and musculoskeletal regeneration.

Short descriptiontext

Cellcolabs is a Swedish biotech producing GMP-certified mesenchymal stem cells (MSCs) at industrial scale, supplying university hospitals, research institutions, biotech companies, and clinics globally while operating clinical subsidiaries in the Bahamas, UAE, and Southeast Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mesenchymal stem cells, GMP cell manufacturing, regenerative medicine, clinical trial supply, cell therapy production
Industry4 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
Cell Therapy Manufacturing
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Stem Cell Product Sales
TypeOne Time License
Description

Sale of GMP-certified mesenchymal stem cells to university hospitals, research institutions, biotechnology companies, and clinics globally. The company sells both bone-marrow-derived MSCs and adipose-derived MSCs for clinical research and therapeutic applications.

cellcolabs.com
2Clinical Trial Sponsorship
TypeProfessional Services
Description

Sponsorship of clinical trials through Cellcolabs Clinical subsidiary, assessing MSC therapies for conditions including cardiovascular disease, musculoskeletal injuries, Sjögren's Syndrome, and knee osteoarthritis. Trials conducted in the Bahamas, UAE, and Denmark.

cellcolabs.com
3Clinical Products and Services
TypeOne Time License
Description

Revenue from commercial clinical treatments through Cellcolabs Clinical, with 2025 revenues increasing approximately 40% to around 57 MSEK. Focus on orthopedic applications, particularly knee osteoarthritis treatments.

cellcolabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details3 tiers
1Research-grade MSC products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

GMP-certified mesenchymal stem cells sold to research institutions and pharmaceutical companies. Pricing based on cell doses, passage level, and quantity requirements. Not publicly disclosed; quote-based.

cellcolabs.com
2Clinical trial supply
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Supply of GMP-manufactured adipose-derived mesenchymal stem cells (aMSCs) for clinical trials, such as the Phase I trial at Rigshospitalet Copenhagen for Sjögren's Syndrome.

cellcolabs.com
3Direct-to-consumer clinical treatments
ModelOtherBilling cadencePay-as-you-go
Notes

Physician-led treatments through Cellcolabs Clinical subsidiary serving high-profile individuals and longevity-focused patients. Treatment administered via local injection or systemic infusion.

cellcolabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cellcolabs is a Swedish biotechnology company that produces GMP-certified mesenchymal stem cells (MSCs) derived from bone marrow at industrial scale in its Stockholm facility under Swedish Medical Products Agency oversight. The company supplies these cells to university hospitals, research institutions, and biotechnology companies for clinical research and therapeutic applications, and also sponsors clinical trials and offers cell therapy access through its Cellcolabs Clinical subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90% cost reduction target for MSC production by 2035
+3 more records
Product overview1 text field

Cellcolabs is a Swedish biotech company that specializes in large-scale GMP production of mesenchymal stem cells (MSCs). The company's core product is GMP-certified Mesenchymal Stem Cells manufactured in Stockholm under Swedish Medical Products Agency oversight. Cellcolabs operates through subsidiaries including Cellcolabs Clinical for clinical trial sponsorship and Cellcolabs Asia for Southeast Asian commercialization. The company also operates a bone marrow donation program to source cells for production. Their production process, developed over 25 years at the Karolinska Institutet, aims to make high-quality stem cells available at industrial scale with a goal of reducing costs by 90% by 2035.

Product and service3 records
1GMP Mesenchymal Stem Cells (MSCs)
CategoryCell Therapy Manufacturing
Description

GMP-certified bone-marrow-derived and adipose-derived mesenchymal stem cells cryopreserved at Passage 3 for optimal potency, supplied to university hospitals, research institutions, biotech companies, and clinics for clinical research and therapeutic applications. Each batch is produced under Swedish Medical Products Agency oversight with full traceability.

2Clinical Trial Services (Cellcolabs Clinical)
CategoryClinical Trial Services
Description

Sponsorship and management of clinical trials assessing MSC therapies for indications including cardiovascular disease, musculoskeletal injuries, Sjögren's Syndrome, and knee osteoarthritis, conducted in markets such as the Bahamas, UAE, Denmark, and Hong Kong.

3Phase 2 Knee Osteoarthritis Study
CategoryClinical Trial Services
Description

Phase 2 clinical study evaluating MSC therapy for knee osteoarthritis, sponsored through the Cellcolabs Clinical subsidiary and conducted at Burjeel Medical City in Abu Dhabi.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Center for Neuromusculoskeletal Restorative Medicine (CNRM), Chinese University of Hong Kong
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Strategic collaboration under InnoHK initiative supporting Phase I/II clinical trial of MSC therapy for knee osteoarthritis. Cellcolabs contributes GMP-grade MSCs manufactured using protocols from 25+ years of Karolinska Institutet research. MoU signed at Cellcolabs' Stockholm headquarters.

cellcolabs.com
2Rigshospitalet Copenhagen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-25
Description

Cellcolabs supplies GMP-manufactured adipose-derived mesenchymal stem cells (aMSCs) for a Phase I clinical trial at Rigshospitalet, Copenhagen, assessing MSC treatment for xerostomia in Sjögren's Syndrome patients. First clinical use of Cellcolabs' adipose-derived MSCs in Denmark.

cellcolabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership alliance featured on Cellcolabs' website, indicating collaborative relationship in the regenerative medicine space.

4OA Action Alliance
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership alliance focused on osteoarthritis, aligned with Cellcolabs' priority indication area of knee osteoarthritis treatment.

cellcolabs.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Origin of Cellcolabs' stem cell production technology. Company was founded based on pioneering stem cell research of Professor Katarina Le Blanc at Karolinska Institute. Production protocols developed over 25+ years at the institute. Company operates within KI Science Park ecosystem.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based developer of MSC manufacturing platforms and off-the-shelf MSC products for cell therapy developers. Most directly comparable to Cellcolabs in offering industrial-scale, GMP-grade mesenchymal stem cells to research and clinical customers.

TypeDirect peer
Description

Australian-listed commercial-stage MSC therapy company developing remestemcel-L and other allogeneic MSC products for inflammatory and orthopedic indications. Comparable as an MSC-focused biotech pursuing late-stage clinical trials and commercial supply.

3Cynata Therapeutics
TypeDirect peer
Description

Australia-based clinical-stage biotech using a patented platform to manufacture MSC-based therapies at scale from a single donor source. Comparable in focusing on scalable MSC manufacturing and clinical development in orthopedic and inflammatory indications.

4Pluristem Therapeutics
TypeDirect peer
Description

Israel-based cell therapy company developing placenta-derived MSC-like adherent stromal cell products. Comparable as a non-Karolinska MSC platform targeting orthopedic and regenerative medicine indications.

TypeDirect peer
Description

German-based supplier of GMP-grade raw materials and contract manufacturing services for cell and gene therapy developers. Comparable as a GMP-focused cell therapy manufacturing services provider serving academic and commercial customers globally.

TypeBroad incumbent
Description

Global life-science tools and cell therapy manufacturing company offering MSC products, cell processing instruments, and CDMO services. Comparable as a broader incumbent providing MSC-related products and GMP manufacturing infrastructure across the cell therapy value chain.

TypeBroad incumbent
Description

Swiss multinational CDMO with large-scale cell and gene therapy manufacturing capabilities, including MSC-related services. Comparable as a broad incumbent in cell therapy contract manufacturing with global GMP capacity.

TypeBroad incumbent
Description

Major global CDMO with cell therapy manufacturing services acquired by Novo Holdings in 2024. Comparable as a broad incumbent offering industrial-scale cell therapy development and manufacturing services to biotech customers.

TypeEmerging player
Description

US-based allogeneic T-cell and MSC-derived therapy developer. Comparable through its focus on off-the-shelf cell therapies and because incoming Cellcolabs CEO Vincent Metzler previously held leadership roles there.

TypeEmerging player
Description

US-based manufacturer of iPSC-derived cells and cell therapy manufacturing services. Comparable as a specialized industrial-scale cell manufacturer serving research and clinical customers, though focused on iPSC rather than bone marrow-derived MSCs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellcolabs

Cell Therapy Manufacturingcellcolabs.com

Cellcolabs is a Swedish biotech producing GMP-certified mesenchymal stem cells (MSCs) at industrial scale, supplying university hospitals, research institutions, biotech companies, and clinics globally while operating clinical subsidiaries in the Bahamas, UAE, and Southeast Asia.

What Cellcolabs does

Cellcolabs is a Swedish biotech founded in 2021 that produces GMP-certified mesenchymal stem cells (MSCs) at industrial scale for both research supply and clinical therapeutic use. Manufacturing is conducted at a GMP-certified facility in Stockholm under oversight of the Swedish Medical Products Agency (Läkemedelsverket), with the underlying production protocol developed over 25+ years at Karolinska Institutet by Professor Katarina Le Blanc. A single bone marrow donation is reported to yield up to 200 therapeutic doses, and the company has publicly targeted a 90% reduction in MSC production cost by 2035 through scaled manufacturing.

The company serves four primary customer segments: university hospitals, academic and translational research institutions, biotech and pharmaceutical companies, and clinics offering MSC-based treatments. It operates dedicated regional vehicles — Cellcolabs Asia (Bangkok) for Southeast Asia commercialization and Cellcolabs Clinical (Bahamas/UAE) — which provide direct-to-clinic and DTC channels in jurisdictions where cell-therapy patient flows are accessible. The revenue model combines product sales of MSC batches to research customers, sponsorship of clinical trials at named academic medical centers (e.g., Rigshospitalet, InnoHK CNRM, Burjeel Medical City), and clinical treatments delivered through partner clinics.

Strategic positioning has shifted materially in 2025–2026: a $12M funding round closed in October 2025 to support international expansion, a new CEO with senior biotech/big-pharma pedigree (Vincent Metzler) was appointed in June 2026, and the company underwent a restructuring to prioritize B2B commercialization and orthopedic indications — notably knee osteoarthritis — alongside ongoing work in Sjögren's Syndrome and musculoskeletal regeneration.

Cellcolabs firmographics

Firmographics
Name
Cellcolabs
Legal name
Cellcolabs AB
Website
https://cellcolabs.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Cellcolabs is a Swedish biotech producing GMP-certified mesenchymal stem cells (MSCs) at industrial scale, supplying university hospitals, research institutions, biotech companies, and clinics globally while operating clinical subsidiaries in the Bahamas, UAE, and Southeast Asia.
Ownership category
akta.pro rank

Cellcolabs industry classification

Industry
Product category
Cell Therapy Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Mesenchymal stem cells
  • GMP cell manufacturing
  • Regenerative medicine
  • Clinical trial supply
  • Cell therapy production

Where Cellcolabs is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices4 records

Markets served

Cellcolabs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Stem Cell Product Sales: Sale of GMP-certified mesenchymal stem cells to university hospitals, research institutions, biotechnology companies, and clinics globally. The company sells both bone-marrow-derived MSCs and adipose-derived MSCs for clinical research and therapeutic applications.
  2. Clinical Trial Sponsorship: Sponsorship of clinical trials through Cellcolabs Clinical subsidiary, assessing MSC therapies for conditions including cardiovascular disease, musculoskeletal injuries, Sjögren's Syndrome, and knee osteoarthritis. Trials conducted in the Bahamas, UAE, and Denmark.
  3. Clinical Products and Services: Revenue from commercial clinical treatments through Cellcolabs Clinical, with 2025 revenues increasing approximately 40% to around 57 MSEK. Focus on orthopedic applications, particularly knee osteoarthritis treatments.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goResearch-grade MSC products
Unit PricingPay-as-you-goClinical trial supply
OtherPay-as-you-goDirect-to-consumer clinical treatments

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Cellcolabs product offering

Product offering

Core offering

Cellcolabs is a Swedish biotechnology company that produces GMP-certified mesenchymal stem cells (MSCs) derived from bone marrow at industrial scale in its Stockholm facility under Swedish Medical Products Agency oversight. The company supplies these cells to university hospitals, research institutions, and biotechnology companies for clinical research and therapeutic applications, and also sponsors clinical trials and offers cell therapy access through its Cellcolabs Clinical subsidiary.

Product overview

Cellcolabs is a Swedish biotech company that specializes in large-scale GMP production of mesenchymal stem cells (MSCs). The company's core product is GMP-certified Mesenchymal Stem Cells manufactured in Stockholm under Swedish Medical Products Agency oversight. Cellcolabs operates through subsidiaries including Cellcolabs Clinical for clinical trial sponsorship and Cellcolabs Asia for Southeast Asian commercialization. The company also operates a bone marrow donation program to source cells for production. Their production process, developed over 25 years at the Karolinska Institutet, aims to make high-quality stem cells available at industrial scale with a goal of reducing costs by 90% by 2035.

Differentiator

Problem solved

Functional benefit

Products and services

  • GMP Mesenchymal Stem Cells (MSCs) GMP-certified bone-marrow-derived and adipose-derived mesenchymal stem cells cryopreserved at Passage 3 for optimal potency, supplied to university hospitals, research institutions, biotech companies, and clinics for clinical research and therapeutic applications. Each batch is produced under Swedish Medical Products Agency oversight with full traceability.
  • Clinical Trial Services (Cellcolabs Clinical) Sponsorship and management of clinical trials assessing MSC therapies for indications including cardiovascular disease, musculoskeletal injuries, Sjögren's Syndrome, and knee osteoarthritis, conducted in markets such as the Bahamas, UAE, Denmark, and Hong Kong.
  • Phase 2 Knee Osteoarthritis Study Phase 2 clinical study evaluating MSC therapy for knee osteoarthritis, sponsored through the Cellcolabs Clinical subsidiary and conducted at Burjeel Medical City in Abu Dhabi.

Quantifiable outcome

  • 90% cost reduction target for MSC production by 2035
  • +3 more outcomes

Companies that use Cellcolabs

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Cellcolabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cellcolabs partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Center for Neuromusculoskeletal Restorative Medicine (CNRM), Chinese University of Hong KongcoreStrategic or Co-development Partner · 24 February 2026Strategic collaboration under InnoHK initiative supporting Phase I/II clinical trial of MSC therapy for knee osteoarthritis. Cellcolabs contributes GMP-grade MSCs manufactured using protocols from 25+ years of Karolinska Institutet research. MoU signed at Cellcolabs' Stockholm headquarters.
  • Rigshospitalet CopenhagencoreStrategic or Co-development Partner · 25 March 2025Cellcolabs supplies GMP-manufactured adipose-derived mesenchymal stem cells (aMSCs) for a Phase I clinical trial at Rigshospitalet, Copenhagen, assessing MSC treatment for xerostomia in Sjögren's Syndrome patients. First clinical use of Cellcolabs' adipose-derived MSCs in Denmark.
  • PSL AllianceminorStrategic or Co-development PartnerStrategic partnership alliance featured on Cellcolabs' website, indicating collaborative relationship in the regenerative medicine space.
  • OA Action AllianceminorStrategic or Co-development PartnerPartnership alliance focused on osteoarthritis, aligned with Cellcolabs' priority indication area of knee osteoarthritis treatment.
  • Karolinska Institutet / KI Science ParkcoreStrategic or Co-development PartnerOrigin of Cellcolabs' stem cell production technology. Company was founded based on pioneering stem cell research of Professor Katarina Le Blanc at Karolinska Institute. Production protocols developed over 25+ years at the institute. Company operates within KI Science Park ecosystem.

Scale indicators6 records

Recent moves5 records

Expansion highlights7 records

Cellcolabs competitors and assessment

Company assessment

Direct peers

  • RoosterBio: US-based developer of MSC manufacturing platforms and off-the-shelf MSC products for cell therapy developers. Most directly comparable to Cellcolabs in offering industrial-scale, GMP-grade mesenchymal stem cells to research and clinical customers.
  • Mesoblast: Australian-listed commercial-stage MSC therapy company developing remestemcel-L and other allogeneic MSC products for inflammatory and orthopedic indications. Comparable as an MSC-focused biotech pursuing late-stage clinical trials and commercial supply.
  • Cynata Therapeutics: Australia-based clinical-stage biotech using a patented platform to manufacture MSC-based therapies at scale from a single donor source. Comparable in focusing on scalable MSC manufacturing and clinical development in orthopedic and inflammatory indications.
  • Pluristem Therapeutics: Israel-based cell therapy company developing placenta-derived MSC-like adherent stromal cell products. Comparable as a non-Karolinska MSC platform targeting orthopedic and regenerative medicine indications.
  • CellGenix: German-based supplier of GMP-grade raw materials and contract manufacturing services for cell and gene therapy developers. Comparable as a GMP-focused cell therapy manufacturing services provider serving academic and commercial customers globally.

Broad incumbents

  • Miltenyi Biotec: Global life-science tools and cell therapy manufacturing company offering MSC products, cell processing instruments, and CDMO services. Comparable as a broader incumbent providing MSC-related products and GMP manufacturing infrastructure across the cell therapy value chain.
  • Lonza Group: Swiss multinational CDMO with large-scale cell and gene therapy manufacturing capabilities, including MSC-related services. Comparable as a broad incumbent in cell therapy contract manufacturing with global GMP capacity.
  • Catalent (Novo Holdings): Major global CDMO with cell therapy manufacturing services acquired by Novo Holdings in 2024. Comparable as a broad incumbent offering industrial-scale cell therapy development and manufacturing services to biotech customers.

Emerging players

  • Atara Biotherapeutics: US-based allogeneic T-cell and MSC-derived therapy developer. Comparable through its focus on off-the-shelf cell therapies and because incoming Cellcolabs CEO Vincent Metzler previously held leadership roles there.
  • FUJIFILM Cellular Dynamics: US-based manufacturer of iPSC-derived cells and cell therapy manufacturing services. Comparable as a specialized industrial-scale cell manufacturer serving research and clinical customers, though focused on iPSC rather than bone marrow-derived MSCs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellcolabs social profiles

Digital presence

Cellcolabs compliance and trust

Trust signal

Compliance3 records

Cellcolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellcolabs leadership team

Management profile

Number of profiles

Profiles14 records

Cellcolabs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cellcolabs funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellcolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellcolabs

What does Cellcolabs do?

Cellcolabs is a Swedish biotechnology company that produces GMP-certified mesenchymal stem cells (MSCs) derived from bone marrow at industrial scale in its Stockholm facility under Swedish Medical Products Agency oversight. The company supplies these cells to university hospitals, research institutions, and biotechnology companies for clinical research and therapeutic applications, and also sponsors clinical trials and offers cell therapy access through its Cellcolabs Clinical subsidiary.

Is Cellcolabs a public or private company?

Cellcolabs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellcolabs founded?

Cellcolabs was founded in 2021. It employs 51 to 100 people.

Where is Cellcolabs based?

Cellcolabs is headquartered in Solna, Sweden, in the Europe region.

How does Cellcolabs make money?

Three revenue lines are on record. Stem Cell Product Sales are the primary driver. The others are clinical Trial Sponsorship and clinical Products and Services.

Who are Cellcolabs's main competitors?

Direct peers on record are RoosterBio, Mesoblast, Cynata Therapeutics, Pluristem Therapeutics and CellGenix. Broad incumbents are Miltenyi Biotec, Lonza Group and Catalent (Novo Holdings). Emerging players are Atara Biotherapeutics and FUJIFILM Cellular Dynamics.

Does Cellcolabs have an API?

No public API is recorded for Cellcolabs.

What industry is Cellcolabs in?

Cellcolabs's product category is Cell Therapy Manufacturing. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SiftedBryan Johnson’s go-to stem cell startup Cellcolabs lands $12m for worldwide rolloutSwedish stem cell startup Cellcolabs has raised $12 million in funding from Titian Capital through its life-sciences platform, Titian Life Sciences, bringing its total funding to $37 million. The investment will support technical development and the company's international expansion plans. CEO Mattias Bernow is leading the company as it works to make stem cell therapies more accessible to a broader population.Bebeez€10.3 million boost for Sweden’s Cellcolabs to lower global stem cell costs by 90% through scalable manufacturing – BeBeez InternationalCellcolabs, a Stockholm-based BioTech startup focused on scalable mesenchymal stem cell production, has secured €10.3 million in new funding led by Titian Capital through its Titian Life Sciences platform, bringing total funding to €31 million. The investment will support further technical development, production scaling, and global market expansion as the company pursues its goal of reducing MSC costs by 90% by 2035. The funding positions Cellcolabs among Sweden's largest 2025 fundraises in regenerative medicine, signaling growing European confidence in scalable stem-cell manufacturing as a foundation for next-generation cellular therapies.ArcticstartupSwedish Cellcolabs secures $12 million to expand stem cell manufacturing capacitySwedish biotech company Cellcolabs has secured $12 million in funding from Titian Capital's life sciences arm, bringing its total raised capital to $37 million. The company develops large-scale production methods for Mesenchymal Stem Cells used in medical research and clinical applications, with plans to use the funds to advance technical capabilities and expand into international markets. Cellcolabs was founded in 2021 and is working toward reducing the cost of stem cells by 90% by 2035 to democratize access to high-quality stem cells globally.Tech.euCellcolabs secures $12M to drive technical developmentStockholm-based biotech company Cellcolabs has secured $12 million in primary funding from Titian Capital through its life sciences platform, Titian Life Sciences, bringing its total funding to $37 million. The company specializes in industrial-scale production of GMP-certified mesenchymal stem cells for research and clinical applications, with operations centered in Sweden and cells supplied to university hospitals and private clients worldwide. Cellcolabs plans to use the investment to advance technical development and expand internationally, with a stated goal of reducing MSC costs by 90 percent by 2035.Tech Funding NewsBiotech startup Cellcolabs secures $8.7M to make stem cell production affordable — TFNSwedish biotech startup Cellcolabs raised $8.7 million in an oversubscribed funding round aimed at making mesenchymal stem cells (MSCs) more affordable through large-scale production. The company plans to use the funds to scale up research and development, operations, and business development, with a total of $21.5 million raised to date. Cellcolabs aims to transform healthcare by providing high-quality MSCs, essential for treating various diseases, at a fraction of current costs.YahooThis Swedish startup wants to reduce the cost, and controversy, around stem cell productionStockholm-based Cellcolabs raised $8.7 million in a new round, bringing total funding to $21.5 million since 2021. The startup aims to produce mesenchymal stem cells from adult bone marrow, claiming it could cut MSC costs by up to 90% within a decade. The funds will support R&D, operations, and business development.TechCrunchThis Swedish startup wants to reduce the cost, and controversy, around stem cell productionStockholm-based Cellcolabs raised $8.7 million in a new round, bringing total funding to $21.5 million since 2021. The startup aims to produce mesenchymal stem cells from adult bone marrow, claiming it could cut MSC costs by up to 90% within a decade. The company plans to use the funds for R&D, operations, and business development.Dagens industriEvolutions grundare med när Cellcolabs tar in 90 miljonerCellcolabs has secured a 90 million SEK investment round to accelerate the production and commercialization of its stem cell technology. The funding includes participation from Evolution Gaming co-founders Fredrik Österberg and Jens von Bahr, alongside other prominent Swedish investors. This capital injection aims to increase the company's operational capacity in Stockholm.Tech.euSwedish biotech Cellcolabs secures $8.7M for affordable stem cell productionSwedish biotech company Cellcolabs has secured $8.7 million in funding, bringing its total capital raised to $21.5 million. The company aims to use these funds to scale up research and development operations for its industrial-scale production of mesenchymal stem cells, which it intends to sell at significantly reduced costs.